Last Updated: January 2nd, 2026
PICOs prediction supports Joint Clinical Assessment planning across priority European markets, where our team engaged for a precision oncology launch. Early insight clarifies likely assessment scope and supports evidence strategy alignment ahead of submission.
Technical Expertise Supporting JCA Strategy
Specialist expertise in market access, health economics, and clinical strategy informs PICOS prediction, ensuring that assumptions reflect HTA methodology and real-world decision-making contexts relevant to the Joint Clinical Assessment.
Predicting Likely PICOS for JCA Scope
A structured evidence review identifies patient populations, comparators, and outcomes likely to fall within JCA scope, supporting early clarity on assessment focus areas.
- Targeted literature review captures current and emerging comparators.
- Analogue assessment incorporates oncologist insight on treatment positioning.
- Focused desk research identifies relevant analogues and future comparators.
Prioritizing PICOS Across Markets
Validation with country advisors supports market-level prioritization and highlights PICOS scenarios that require deeper evidence consideration or strategic focus.
Practical Agility Supporting Delivery
An iterative and flexible approach supports progress under compressed timelines while maintaining analytical rigor and alignment with evolving development and access priorities.
- Identifying Evidence Gaps and Mitigation Strategies: The available evidence is reviewed against the predicted PICOs to identify gaps. Targeted analyses (AI-assisted SLR and NMA) support practical recommendations to strengthen alignment with Joint Clinical Assessment requirements.
- Delivering Results: Prioritized PICOs informs evidence planning and aligns predictive insights with broader development and access objectives, supporting a more efficient and coordinated JCA process.
- Validating PICOs Through Expert Engagement: Clinical expert input informs initial PICOs assumptions. Payer perspectives support confirmation of final PICOs selections aligned with assessment expectations.
Customer Testimonies
Our Expert Support
Support extends beyond analytical outputs to help teams navigate strategic decisions and evolving assessment dynamics. Ongoing collaboration provides perspective, challenge, and continuity as evidence plans mature and JCA outcomes take shape. Connect with our experts to help support your team.
Learn how PICOS prediction supports JCA readiness
Meet our Outcomes Research Team
Holly Guy
Executive Director
Holly has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has over 30 successful HTA submissions, including those to NICE, SMC, and AWMSG in the UK, as well as in several European countries. She has attended and represented pharma companies at NICE and AWMSG appraisal committee meetings. Holly led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Vicki Laskier
Director
Vicki specializes in the strategy and implementation of HEOR solutions. With extensive experience in developing HTA dossiers, systematic literature reviews, and economic models, she has contributed to over 19 HTA submissions across NICE, SMC, and NCPE. Vicki has also represented companies at HTA meetings, leading the development of tools that support both payer and internal needs. Her work in statistical analysis, including Bayesian methods and network meta-regressions, has been widely used in healthcare decision-making.
FAQs on PICOs Prediction and JCA Strategy
What is PICOs prediction in the context of JCA?
PICOS prediction anticipates populations, comparators, and outcomes likely to be assessed, supporting early evidence alignment before formal Joint Clinical Assessment scoping.Why is early PICOs insight important for JCA planning?
Early insight reduces uncertainty, highlights potential evidence gaps, and supports more informed prioritization ahead of submission timelines.How does PICOs prediction support multi-country alignment?
Predictive analysis helps harmonize assumptions across markets while accounting for differences in clinical practice and assessment priorities.Can PICOs prediction influence evidence generation decisions?
Predictive outputs inform where additional analyses or data generation may be required to support JCA readiness.